Biocon Limited announced its consolidated financial results for the quarter and nine months ended December 31, 2025. The company posted an Operating Revenue of ₹4,173 Crore (up 9% YoY) and an EBITDA of ₹951 Crore (up 21% YoY). Reported Net Profit surged dramatically by 475% to ₹144 Crore. Leadership highlighted the successful integration of Biocon Biologics and strong momentum across biosimilars and generics segments.
Biocon Reports Strong Q3 FY26 Financial Performance
Biocon Limited announced its consolidated financial results for the third quarter ended December 31, 2025. The results reflect a year of strategic restructuring, including the full integration of Biocon Biologics as a wholly owned subsidiary, a move valued at approximately USD 5.5 billion.
Key consolidated financial highlights for Q3 FY26 compared to Q3 FY25:
- Consolidated Revenue: Increased 11% to ₹4,290 Crore.
- Operating Revenue: Grew 9% YoY to ₹4,173 Crore.
- EBITDA: Rose 21% to ₹951 Crore, resulting in a 22% EBITDA Margin.
- Core EBITDA: Increased 21% to ₹1,221 Crore, with margins at 29%.
- Reported Net Profit: Jumped 475% to ₹144 Crore.
- PBT (before exceptional items): Increased 64% to ₹226 Crore.
Leadership Commentary on Strategic Progress
Kiran Mazumdar-Shaw, Chairperson, Biocon Group, highlighted the culmination of strategic steps, emphasizing the ~USD 1 billion raised cumulatively through two QIPs and the strengthening of the balance sheet, reflected in S&P’s upgrade of the Biosimilars business to BB+ with a ‘Stable’ outlook.
Siddharth Mittal, CEO & Managing Director, Biocon Limited, noted that the Generics business achieved strong sequential revenue growth of 10%, driven by ongoing launches of gLiraglutide across EU markets.
Segment-wise Performance (Q3FY26 Revenue from Operations)
The segmental revenue contribution showed Biosimilars remaining the largest contributor:
- Biosimilars (Biocon Biologics): ₹2,497 Crore, marking a 9% YoY growth.
- Generics (APIs & Generic Formulations): ₹851 Crore, growing 24% YoY.
- CRDMO (Syngene): ₹917 Crore, showing a slight decrease of 3% YoY.
The segment breakdown reveals Biosimilars contributed 59%, CRDMO 21%, and Generics 20% of the total revenue from operations.
Biocon Biologics Highlights
The Biosimilars arm reported a robust performance with EBITDA reaching ₹700 crore, a 44% year-on-year increase, driven by strong demand in North America. Strategic pipeline developments included the disclosure of three new biosimilar assets: Trastuzumab subcutaneous (SC), Nivolumab, and Pembrolizumab.
Syngene (CRDMO) Performance
Syngene’s highlight was the extension of its relationship with Bristol Myers Squibb through to 2035, securing a strategic ten-year horizon for collaboration. The business secured new customers, though overall revenue was slightly impacted by a single large molecule client issue.
Corporate and ESG Developments
The company successfully raised ₹4,150 crore (~USD 460 million) via a QIP to primarily fund the buyout of Mylan’s stake in Biocon Biologics. In ESG metrics, Biocon Limited improved its S&P score to 73 (a 5-point improvement).
Upcoming Earnings Call
Management will discuss these results on the Earnings Call scheduled for February 13, 2026, at 9:00 AM IST via webcast.
Source: BSE
